AMSTERDAM, June 3, 2019 /PRNewswire/ — Elsevier, the information analytics business specializing in science and health, today released the 2018 CiteScore values, its latest assessment of thousands of all peer-reviewed research journals, book series, conference proceedings and trade publications covered in Scopus. These new values are available for free.
This year more than 23,830 titles source titles covering 330 disciplines were ranked across eight indicators, which are all part of CiteScore metrics. These include: CiteScore, CiteScore Tracker, CiteScore Percentile, CiteScore Quartiles, CiteScore Rank, Citation Count, Document Count, and Percentage Cited. Calculating values for all titles included in Scopus, CiteScore covers 12,000+ more titles than the Impact Factor.
Access to CiteScore metrics’ underlying data is free for everyone, including non-Scopus subscribers, so values can be recalculated offering transparency to researchers, publishers and the wider academic community. New this year is that calculations can be broken down by document type, enabling user-defined alternative CiteScore calculations including only certain document types.
“Based on user feedback, this year we are offering a new functionality to include document type presets,” explained Andrew Plume, Director Research Evaluation, Elsevier. “Alongside the inclusion of all document types in the default CiteScore calculation, users can see the effect of manually restricting the calculation to any of three different sets of document types in both the numerator (i.e., citations counted), and denominator (i.e., publications counted). This provides additional transparency relating to the way certain document types might impact a title’s CiteScore value.”
CiteScore metrics are part of a collection of research metrics available on or through Scopus. Other metrics include journal, author, institutional, and article-level metrics captured in PlumX Metrics (covering Usage, Captures, Mentions, Social Media and Citations), supporting a holistic view of research performance.
“By making available a suite of citation and non-citation-based metrics, we underscore one of the two golden rules of research evaluation (i.e., to always use two or more complementary quantitative indicators; the other rule is to always use indicators alongside expert judgement,” added Plume. “With this approach Elsevier is responsive to the needs of researchers and research leaders and is constantly scanning the horizon for useful new metrics to add to the array.”
With CiteScore Tracker journal performance can be monitored throughout the year, alongside the release of the annual score.
For a complete overview 2018 CiteScore values – and all other research metrics available in Scopus – go to: CiteScore 2018 metrics.
CiteScore metrics, including access to the underlying data, are free to access without a Scopus subscription in the following ways:
About Elsevier
Elsevier is a global information analytics business that helps scientists and clinicians to find new answers, reshape human knowledge, and tackle the most urgent human crises. For 140 years, we have partnered with the research world to curate and verify scientific knowledge. Today, we’re committed to bringing that rigor to a new generation of platforms. Elsevier provides digital solutions and tools in the areas of strategic research management, R&D performance, clinical decision support, and professional education; including ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath. Elsevier publishes over 2,500 digitized journals, including The Lancet and Cell, 39,000 e-book titles and many iconic reference works, including Gray’s Anatomy. Elsevier is part of RELX Group, a global provider of information and analytics for professionals and business customers across industries. www.elsevier.com
Media contact
Sacha Boucherie, Global Communications
Elsevier
s.boucherie@elsevier.com
View original content:http://www.prnewswire.com/news-releases/elsevier-releases-2018-citescore-values-300860509.html
SOURCE Elsevier
Hemogenyx Pharmaceuticals Receives IRB Approval for Phase 1 Clinical Trial of HEMO-CAR-T (HG-CT-1)LONDON, UK /…
SAN DIEGO, CA / ACCESSWIRE / November 21, 2024 / Modular Medical, Inc. (Nasdaq:MODD) ("Modular…
BEVERLY HILLS, CALIFORNIA / ACCESSWIRE / November 21, 2024 / Nicole Garrett, CEO of Under…
HUNTINGTON BEACH, Calif., Nov. 21, 2024 /PRNewswire/ -- Beacon Healthcare Systems, is pleased to announce…
Attributes Revenue Growth to Innovative Partnerships, Strong Team, and Unique Value-Based Care Model NEW YORK,…
Automation That Makes a Difference SUNRISE, Fla., Nov. 21, 2024 /PRNewswire/ -- When it comes…